Does the Future of Prostate Cancer Treatment Lie with Apoptotic Inducers?
Journal Title: Üroonkoloji Bülteni - Year 2017, Vol 16, Issue 1
Abstract
Despite present-day clinical achievements which can extend the overall survival period, prostate cancer (PCa) related mortality remains a major problem. Resistance against apoptosis which consequently leads to disease prognosis is one of the most important characteristics of metastatic cancer cells which display a high level of genetic and clinical heterogeneity. Therefore, achievements in the local treatment of PCa have not been matched in the treatment of the metastatic disease. Although androgen deprivation therapy is the standard treatment due to the androgen receptor (AR) signaling pathway which has primary importance in metastatic cases, successful treatment remains difficult because of the genetic aberrations of ARs. Majority of the PCa patients develop resistance against androgen ablation within an average of 12-36 month-period and despite the castrate levels of testosterone, androgen-dependent and independent signals cause an increase in the cancer cells. While effective survival advantages displayed by the new generation agents like abiraterone and enzalutamide is promising in the treatment of metastatic castration resistant PCa how to best manage the primary and secondary resistance to treatment remains a challenge. The apoptotic effect enhancing pro-survival effectors and apoptotic regulators within the cytoprotective chaperone networks become more and more important every day for overcoming treatment resistance. Recent scientific research on apoptotic pathway inducing mechanisms focuses on the importance of developing synergistic treatment strategies. Molecules with lower side-effect profiles which are capable of inducing physiological mechanisms like apoptosis are expected to replace chemotherapeutic agents in the future.
Authors and Affiliations
Ece Konaç, Sinan Sözen
Keywords
Related Articles
- EP ID EP226742
- DOI 10.4274/uob.606
- Views 82
- Downloads 0
Can High Preoperative Neutrophil-lymphocyte Ratio Predict the Recurrence and Progression Risk of Non-muscle-invasive Bladder Tumors?
Objective: Neutrophil-lymphocyte ratio (NLR) is a well-known, cost-effective biomarker of inflammatory conditions, and its protumor effect has been shown in different types of cancers. In this study, we aimed to evaluate...
The Relationship between Bladder Cancer and Epigenetic Alterations
Bladder cancer is one of the most common cancers of urinary system and approximately 70% of the cases are low grade and non-muscle invasive. Because of the histological indicator inadequacy of heterogeneous tumors like b...
Targeted Agents and Resistance Mechanism in Renal Cell Cancer
Renal cell carcinoma (RCC) exhibits multidrug resistance protein P-glycoprotein expression due to the proximal tubular origin and in this regard, it is resistant to a large number of cytotoxic chemotherapy. The identific...
Sentinel Lymph Node Biopsy in Lymphadenectomy for Prostate Cancer
Performing the sentinel lymph node (SLN) biopsy during prostate cancer staging aims to provide more accurate nodal staging with low complications than pelvic lymph node dissection. SLN might be found outside the extended...
Evaluation of Testicular Self-examination Technique and Testis Cancer Knowledge Levels of Final-year Medical Students
Objective: The aim of this study was to evaluate the adequacy of knowledge regarding testicular self-examination (TSE) in final-year medical students and determine the TSE performance rate among male students. Materials...